sec filing
CA
NASDAQ · CABA
Cabaletta Bio, Inc.
Healthcare · Biotechnology
$2.60
Down-$0.32 (-10.82%)
Updated Sep 16, 2026, 10:59 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 227.19M
- P/E ratio
- -1.52
- Dividend yield
- 0.00%
- 52-week range
- $2.45 – $4.23
- Volume
- 7.24M
- Avg. volume
- 4.22M
Price performance
CABA price history
1M range · 20 trading sessions · Daily adjusted prices
CABA closed at $2.60 after 20 trading sessions, down 10.82% for the selected period.
- Last close
- $2.60
- Period change
- -10.82%
- Period low
- $2.60
- Period high
- $3.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.89 | $2.92 | $2.57 | $2.595 | 7.24M |
| Sep 14, 2026 | $2.72 | $3.04 | $2.71 | $2.91 | 6.31M |
| Sep 11, 2026 | $2.77 | $2.886 | $2.67 | $2.73 | 7.44M |
| Sep 10, 2026 | $2.85 | $2.875 | $2.69 | $2.74 | 7.08M |
| Sep 9, 2026 | $3.28 | $3.28 | $2.90 | $2.91 | 6.51M |
| Sep 8, 2026 | $3.43 | $3.48 | $3.26 | $3.27 | 3.07M |
| Sep 4, 2026 | $3.46 | $3.60 | $3.40 | $3.47 | 4.89M |
| Sep 3, 2026 | $3.63 | $3.75 | $3.47 | $3.48 | 7.44M |
| Sep 2, 2026 | $3.27 | $3.58 | $3.25 | $3.57 | 8.05M |
| Sep 1, 2026 | $3.00 | $3.315 | $2.84 | $3.30 | 6.65M |
| Aug 31, 2026 | $3.105 | $3.205 | $3.08 | $3.11 | 3.03M |
| Aug 28, 2026 | $3.36 | $3.375 | $3.11 | $3.12 | 3.24M |
| Aug 27, 2026 | $3.24 | $3.445 | $3.23 | $3.38 | 3.8M |
| Aug 26, 2026 | $3.20 | $3.27 | $3.17 | $3.25 | 2.49M |
| Aug 25, 2026 | $3.14 | $3.2791 | $3.11 | $3.22 | 3.97M |
| Aug 24, 2026 | $3.09 | $3.17 | $3.01 | $3.10 | 3.11M |
| Aug 21, 2026 | $3.20 | $3.34 | $3.085 | $3.13 | 4.4M |
| Aug 20, 2026 | $3.04 | $3.24 | $2.95 | $3.19 | 5.74M |
| Aug 19, 2026 | $2.95 | $3.275 | $2.925 | $3.10 | 10.45M |
| Aug 18, 2026 | $2.89 | $2.96 | $2.82 | $2.91 | 6.98M |
Latest CABA news
The latest Smart Investors Daily articles mentioning CABA.
Stock researchCompany · Overview
CABA research
Overview
Company profile and research snapshot.
Company profile
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $16.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | Wells Fargo | Equal-Weight | — |
| May 15, 2026 | Wells Fargo | Equal-Weight | — |
| May 4, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 24, 2026 | Guggenheim | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.